Metabolic effects of liraglutide in type 2 diabetic patients.

Mariola Mendez Muros; Cristobal Morales Portillo; Antonio Manuel Garrido Hermosilla; Vianney Magaly Santiago Septimo; Antonio  Perez; Victor Sanchez Margalet; Maria Asuncion Martinez Brocca

doi:10.1530/endoabs.56.P499

P499

Prev Next

Section Contents Cite

Endocrine Abstracts (2018) 56 P499 | DOI: 10.1530/endoabs.56.P499

ECE2018 Poster Presentations: Diabetes, Obesity and Metabolism Diabetes therapy (43 abstracts)

Metabolic effects of liraglutide in type 2 diabetic patients.

Mariola Mendez Muros , Cristobal Morales Portillo , Antonio Manuel Garrido Hermosilla , Vianney Magaly Santiago Septimo , Antonio Perez Perez , Victor Sanchez Margalet & Maria Asuncion Martinez Brocca

Views

Author affiliations

Virgen Macarena University Hospital, Seville, Spain.

Objectives: Obesity and type 2 diabetes mellitus (DM2) are risk factors for non-alcoholic fatty liver disease (NAFLD). The main objective was to study the incidence of NAFLD using the Hepatic Steatosis Index (HSI) in obese patients with DM2. Secondary objectives were to analyse the effect of liraglutide over HSI, body mass index (BMI) and glycated hemoglobin (HbA1c).

Methods: Retrospective observational study of obese type 2 diabetic patients treated with liraglutide during the period 2009-2015. Diagnosis of NAFLD was based on the HSI formula=8×(ALT/AST ratio) + BMI (+2, if female; +2, if diabetic).

Results: Study sample of 53 patients, 55% males and 45% females, with a mean age of 49.6 years. 100% of patients presented a positive HSI, which improved in 73.5% of them after treatment with liraglutide. Mean HSI after treatment was significantly lower compared to the previous value (p=0.008). Mean BMI and HbA1c after liraglutide implementation were also significantly lower than before treatment (P=6.004⁻⁰⁶ and P=1.074⁻⁰⁸, respectively). Triglyceride levels decreased in 60% of patients without statistical significance (P=0.054).

Conclusions: After 3 months of treatment with liraglutide, there was an improvement in HSI, BMI and HbA1c, as well as a reduction in triglyceride levels.